Last updated: October 25, 2026

Application No. 18/461,179

INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF

Non-Final OA

Filed

Sep 05, 2023

Priority

Apr 17, 2020 — provisional 63/012,039 +13 more

Examiner

MCDOWELL, BRIAN E

Art Unit

1624

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Pardes Biosciences Inc.

OA Round

3 (Non-Final)

Interview Optional

— +31.0% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 74% grant rate with +31.0% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 1139 resolved cases, 2023–2026

Examiner Intelligence

MCDOWELL, BRIAN E View full profile →

Grants 74% — above average

Career Allowance Rate

843 granted / 1139 resolved

+14.0% vs TC avg

Strong +31% interview lift

Without

With

+31.0%

Interview Lift

resolved cases with interview

Typical timeline

2y 2m

Avg Prosecution

67 currently pending

Career history

1193

Total Applications

across all art units

Statute-Specific Performance

§101

1.0%

-39.0% vs TC avg

§103

16.6%

-23.4% vs TC avg

§102

20.1%

-19.9% vs TC avg

§112

49.8%

+9.8% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1139 resolved cases

Prosecution Timeline

Sep 05, 2023

Application Filed

Apr 22, 2025

Non-Final Rejection mailed

Oct 22, 2025

Response Filed

Dec 18, 2025

Final Rejection mailed

Jun 18, 2026

Request for Continued Examination

Jun 22, 2026

Response after Non-Final Action

Jul 22, 2026

Examiner Interview (Telephonic)

Jul 27, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/187,431

Patent 12753196

ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES

3y 6m to grant Granted Oct 06, 2026

18/210,068

Patent 12753167

INTERMEDIATE OF BILIVERDIN, AND PREPARATION METHOD AND USE THEREOF

3y 3m to grant Granted Oct 06, 2026

18/337,476

Patent 12747223

N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES

3y 3m to grant Granted Sep 29, 2026

17/802,815

Patent 12741943

Sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate, its preparation and use

4y 0m to grant Granted Sep 22, 2026

18/595,801

Patent 12741959

Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host Disease

2y 6m to grant Granted Sep 22, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

74%

Grant Probability

99%

With Interview (+31.0%)

2y 2m (~0m remaining)

Median Time to Grant

High

PTA Risk

Based on 1139 resolved cases by this examiner. Grant probability derived from career allowance rate.